Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.20 USD
Change Today -0.18 / -0.98%
Volume 277.4K
VIVO On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

meridian bioscience inc (VIVO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/14 - $21.22
52 Week Low
01/2/15 - $15.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

meridian bioscience inc (VIVO) Related Bloomberg News

View More Bloomberg News

meridian bioscience inc (VIVO) Related Businessweek News

No Related Businessweek News Found

meridian bioscience inc (VIVO) Details

Meridian Bioscience Inc., an integrated life science company, manufactures, develops, sells, and distributes diagnostic test kits. These are used primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. It also makes and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. In addition, it contract-manufactures proteins and other biologicals for biopharmaceutical and biotechnology companies researching new drugs and vaccines. Its products and technologies are marketed to hospitals, reference labs, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in about 60 countries. Meridian, founded in 1976, is based in Cincinnati.

550 Employees
Last Reported Date: 12/1/14
Founded in 1976

meridian bioscience inc (VIVO) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $602.9K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $263.3K
Executive Vice President of Operations and In...
Total Annual Compensation: $408.9K
President of Meridian Bioscience Europe and M...
Total Annual Compensation: $356.7K
Executive Vice President and President of Mer...
Total Annual Compensation: $307.0K
Compensation as of Fiscal Year 2014.

meridian bioscience inc (VIVO) Key Developments

Meridian Bioscience, Inc. Announces Executive Changes

Meridian Bioscience, Inc. announced that following the passing of Meridian's founder and Chairman Bill Motto, the company appointed CEO Jack Krauetler as Chairman.

Meridian Bioscience Declares Regular Quarterly Cash Dividend for the Second Quarter Ended March 31, 2015, Payable on May 14, 2015

The Board of Directors of Meridian Bioscience, Inc. declared the regular quarterly cash dividend of $0.20 per share for the second quarter ended March 31, 2015. The dividend is of record May 4, 2015 and payable May 14, 2015. This annual indicated dividend rate of $0.80 per share remains the same as the rate in fiscal 2014.

Meridian Bioscience, Inc. Announces Unaudited Earnings Results for Second Quarter and Six Months Ended March 31, 2015; Reaffirms Earnings Guidance for the Fiscal Year Ending September 30, 2015

Meridian Bioscience, Inc. announced unaudited earnings results for second quarter and six months ended March 31, 2015. For the quarter, the company reported net revenues of $51,545,000, operating income of $15,732,000, earnings before income taxes of $15,527,000, net earnings of $10,070,000 or $0.24 per diluted share compared to the net revenues of $50,134,000, operating income of $15,666,000, earnings before income taxes of $15,644,000, net earnings of $10,300,000 or $0.24 per diluted share for the same quarter a year ago. For the six months period, the company reported net revenues of $99,558,000, operating income of $28,401,000, earnings before income taxes of $27,620,000, net earnings of $17,971,000 or $0.43 per diluted share compared to the net revenues of $94,928,000, operating income of $27,292,000, earnings before income taxes of $27,054,000, net earnings of $17,726,000 or $0.42 per diluted share for the same period a year ago. For the fiscal year ending September 30, 2015, management expected net revenues to be in the range of $193 million to $200 million and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 41.9 million at fiscal 2014 year end to approximately 42.4 million at fiscal 2015 year end.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIVO:US $18.20 USD -0.18

VIVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ERBA Diagnostics Inc $2.72 USD -0.02
GenMark Diagnostics Inc $9.17 USD -0.20
Luminex Corp $16.77 USD +0.36
Quidel Corp $21.67 USD -0.57
T2 Biosystems Inc $16.79 USD -0.24
View Industry Companies

Industry Analysis


Industry Average

Valuation VIVO Industry Range
Price/Earnings 22.0x
Price/Sales 4.0x
Price/Book 4.8x
Price/Cash Flow 21.9x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDIAN BIOSCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at